In 2,749 people with type 2 diabetes, the daily pill also beat insulin on blood sugar and weight, though 62% reported stomach side effects. Results were presented at EASD.
Recap by typeshit. Full story at Medical Dialogues.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
On Longevity.Technology's podcast, the two contrast well-studied GLP-1 drugs with thinly tested compounds and discuss gray-market risks and testing.
13:00
A short video on what else people may be losing besides fat while on tirzepatide, a point raised often around muscle loss on GLP-1 drugs.
Loading…